Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-guided secondary prevention after acute coronary syndrome
ACTRN12619001445167Phase 4Recruiting
- Sponsor
- Professor Rob Doughty
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of carvedilol in acute coronary syndrome (ACS) and coronary arteriosclerosis (2 arms), sponsored by Professor Rob Doughty. Primary endpoints: Composite outcome of time to first event of death from any cause or cardiovascular readmission and Hierarchical composite stratified by baseline risk. Started Dec 2019; status: recruiting.
02
Drugs
carvedilol
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12619001445167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001445167.